CAS 190448-56-7

3-O-Acetyl Ezetimibe 2,3,4-Tri-O-acetyl-b-D-glucuronide Methyl Ester

CAS : 190448-56-7

Formule : C₃₉H₃₉F₂NO₁₃

Couleur et forme : Solid

Masse moléculaire : 767.7227

Ref: IN-DA002EKY

3-O-Acetyl Ezetimibe 2,3,4-Tri-O-acetyl-β-D-glucuronide Methyl Ester

Produit contrôlé

CAS : 190448-56-7

Applications Intermediate in the preparation of Phase-II metabolites of Ezetimibe. Glucuronide azetidinone cholesterol absorption inhibitor.
References Mutlib, A., et al.: Drug Metab. Dispos., 20, 451 (1992), Clader, J., et al.: J. Med. Chem., 39, 3684 (1996), van Heek, M., et al.: J. Pharmacol. Exp. Ther., 283, 157 (1997),

Formule : C₃₉H₃₉F₂NO₁₃

Couleur et forme : Neat

Masse moléculaire : 767.72

Ref: TR-A173800

3-o-Acetyl ezetimibe-d4 2,3,4-tri-o-acetyl-β-D-glucuronide methyl ester

CAS : 190448-56-7

Ezetimibe is a potent inhibitor of cholesterol absorption. It inhibits the intestinal absorption of cholesterol by binding to the NPC1L1 protein, which is expressed in the brush border membrane of enterocytes. Ezetimibe competes with dietary cholesterol for the NPC1L1 protein, thereby preventing the transport of cholesterol across the intestinal wall and into the body. This drug has been shown to decrease total and low-density lipoprotein (LDL) cholesterol levels, as well as Apolipoprotein B levels in humans. The mechanism of action for ezetimibe is not fully understood but is thought to be due in part to its ability to inhibit sterol regulatory element-binding proteins (SREBPs). Ezetimibe has also been shown to activate peroxisome proliferator-activated receptor-gamma (PPARγ), increase high-density lipoprotein (HDL) levels, and inhibit platelet aggregation.

Formule : C₃₉H₃₉F₂NO₁₃

Degré de pureté : Min. 95%

Masse moléculaire : 767.7 g/mol

Ref: 3D-QHA44856

3-O-Acetyl Ezetimibe 2,3,4-Tri-O-acetyl-β-D-glucuronide Methyl Ester

CAS : 190448-56-7

Formule : C₃₉H₃₉F₂NO₁₃

Masse moléculaire : 767.72

Ref: ST-EA-CP-E6098